1. 3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC. (September 2015) Authors: Soo, R.A.; Kim, D.W.; Yang, J.C.H.; Stammberger, U.; Xiong, H.; Ihling, C.; Wu, Y.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies. (September 2015) Authors: Ahn, M.J.; Tsai, C.M.; Yang, J.C.H.; Shepherd, F.A.; Satouchi, M.; Kim, D.W.; Bazhenova, L.; Hirashima, T.; Rukazenkov, Y.; Cantarini, M.; Mann, H.; Ramalingam, S.S.; Mitsudomi, T.; Jänne, P.A.; Goss, G.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). (September 2015) Authors: Barlesi, F.; Dingemans, A.M.C.; Ou, I.; Ahn, J.S.; Petris, L.D.; Kim, D.W.; Yang, J.C.H.; Hughes, B.; Lena, H.; Moro-Sibilot, D.; Bearz, A.; Viteri, S.; Mekhail, T.; Spira, A.; Zeaiter, A.; Bordogna, W.; Sturm, C.; Golding, S.; Morcos, P.N.; Govindan, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies. (September 2015) Authors: Goss, G.D.; Yang, J.C.H.; Ahn, M.J.; Tsai, C.M.; Bazhenova, L.; Sequist, L.V.; Ramalingam, S.S.; Shepherd, F.A.; Ghiorghiu, S.; Cantarini, M.; Mann, H.; Mitsudomi, T.; Jänne, P.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7). (February 2017) Authors: Hirsh, V.; Park, K.; Tan, E.H.; Zhang, L.; O'Byrne, K.; Boyer, M.; Yang, J.C.H.; Mok, T.; Lee, K.H.; Lu, S.; Shi, Y.; Kim, S.W.; Laskin, J.; Kim, D.W.; Laurie, S.A.; Kölbeck, K.; Fan, J.; Dodd, N.; Märten, A.; Paz-Ares, L. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. (February 2017) Authors: Schuler, M.; Paz-Ares, L.; Sequist, L.V.; Tan, E.H.; Mok, T.; Hirsh, V.; O'Byrne, K.; Zhang, L.; Yamamoto, N.; Boyer, M.; Shah, R.; Bennouna, J.; Dickgreber, N.J.; De Grève, J.; Love, J.; Märten, A.; Fan, J.; Ehrnrooth, E.; Park, K.; Yang, J.C.H. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma. (December 2016) Authors: Lin, C.C.; Su, W.C.; Chao, Y.; Lee, J.H.; Hsu, C.H.; Cheng, A.L.; Chung, W.P.; Chen, M.H.; Lin, C.L.; Ho, H.L.; Huang, L.P.; Huang, C.T.; Hsueh, S.P.; Yang, J.C.H. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗